{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:57:51Z","timestamp":1778086671993,"version":"3.51.4"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jfo.2017.10.019","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T19:19:51Z","timestamp":1528917591000},"page":"e291-e292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Panuv\u00e9ite s\u00e9v\u00e8re li\u00e9e \u00e0 un traitement par vemurafenib pour un m\u00e9lanome cutan\u00e9 m\u00e9tastatique"],"prefix":"10.1016","volume":"41","author":[{"given":"M.","family":"Boich\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-B.","family":"Conart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Angioi-Duprez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2017.10.019_bib0045","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2017.10.019_bib0050","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2017.10.019_bib0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2017.10.019_bib0060","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ajo.2015.07.035","article-title":"Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase kinase inhibitors: a case series","volume":"160","author":"Niro","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2017.10.019_bib0065","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-14-0776","article-title":"FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation","volume":"20","author":"Kim","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfo.2017.10.019_bib0070","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajo.2014.07.003","article-title":"Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib","volume":"158","author":"Choe","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2017.10.019_bib0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/1471-2407-13-561","article-title":"Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma","volume":"13","author":"Wolf","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jfo.2017.10.019_bib0040","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jamaophthalmol.2014.3024","article-title":"Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib","volume":"132","author":"Guedj","year":"2014","journal-title":"JAMA Ophthalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018155121830216X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018155121830216X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:08:05Z","timestamp":1759259285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S018155121830216X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S018155121830216X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2017.10.019","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Panuv\u00e9ite s\u00e9v\u00e8re li\u00e9e \u00e0 un traitement par vemurafenib pour un m\u00e9lanome cutan\u00e9 m\u00e9tastatique","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2017.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}